Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second‐line therapy with BCR‐ABL1 ≤10% and no major molecular response

British Journal of Haematology, EarlyView.

Source: British Journal of Haematology - October 19, 2018 Category: Hematology Authors: Simone Bonecker, Gabriela Carvalho, Jane Dobbin, Ilana Zalcberg, Rony Schaffel Source Type: research